SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - [ Vista Partners ] announced today that it has updated coverage on [ Ohr Pharmaceutical, Inc. ] (OTCBB: [ OHRP ]) ("The Company" or "OHR") with a twelve month target price of $3.50. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is developing two drugs: Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD) & OHR/AVR 118, in a Phase 2 trial, for the treatment of Cancer Cachexia. Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by [ Genentech ] (acquired by Roche), as well as [ Regeneron's ] aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined could garner approximately $5B in revenues in 2012. OHR's Wet-AMD clinical candidate Squalamine eye drops, in a Phase 2 trial, seems to present a significant advantage relative to the aforementioned therapies considering the delivery method which is self-administered eye drops. Both Lucentis® and Eylea® require an injection into the back of the eye. Earlier this year, Squalamine Eye Drops were awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) for its potential treatment of Wet-AMD. The Squalamine Eye Drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD."

To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit [ http://www.vistapglobal.com ] and click the "Download" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of [ profitable investment ideas ].

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...

Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website [ www.vistapglobal.com ].